Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies
Author:
Affiliation:
1. Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,
2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Publisher
Japanese Society for Lymphoreticular Tissue Research
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jslrt/60/4/60_20002/_pdf
Reference51 articles.
1. 1 Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019; 16: 684-701.
2. 2 Burger JA, O’Brien S. Evolution of CLL treatment— from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018; 15: 510-527.
3. 3 Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019; 94: 1266-1287.
4. 4 Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood. 2019; 134(Supplement_1): 31.
5. 5 Sharman JP, Coutre SE, Furman RR et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019; 37: 1391-1402.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia;Applied Health Economics and Health Policy;2023-08-22
2. Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance;Journal of Clinical and Experimental Hematopathology;2022
3. Predicting In Vivo Drug–Drug Interactions Between Rivaroxaban and Tyrosine Kinase Inhibitors Arising from Mechanism-Based Inactivation of Cytochrome P450 3A4;IRC-SET 2021;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3